Faculty profile
Hugh McMillan
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Queen's University directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $2,689,733
A Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal hB-A Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
CIHR · 2023 · Principal investigator
- $672,433
A Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal hB-A Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
CIHR · 2023 · Principal investigator
A Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal hB-A Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
Principal investigators: Walia, Jagdeep S; McMillan, Hugh J
Keywords: Adeno-Associated Virus; Gene Therapy; Gm2 Gangliosidosis; Infantile; Lysosomal Storage Disease
A Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal hB-A Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
Principal investigators: Walia, Jagdeep S; McMillan, Hugh J
Keywords: Adeno-Associated Virus; Gene Therapy; Gm2 Gangliosidosis; Infantile; Lysosomal Storage Disease
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.